Carcinogenicity testing checks if a compound can cause cancer or abnormal cell growth. It uses long-term animal studies and lab-based cell tests to give clear results. This testing is important for understanding the safety of small molecules, biologics, and natural products before further development. BOC Sciences provides a full range of services, including long-term animal studies, fast transgenic mouse models, site-specific tests, DNA mutation checks, and computer-based predictions. With advanced lab equipment, high-throughput analysis, and expert support, we deliver accurate, reliable data. Our clients include pharmaceutical companies, biotech firms, specialty pharma, and research partners who need clear, actionable insights.
We conduct 2-year rat and mouse studies via oral, dermal, inhalation, or injection routes. Animals are carefully monitored throughout, and comprehensive pathology and tumor incidence data are collected, providing robust, mechanism-informed insights into the chronic carcinogenic potential of tested compounds.
We integrate systemic toxicity and tumor formation evaluations in a single long-term study. This approach improves efficiency while delivering detailed data on general toxicity and carcinogenic outcomes, supporting actionable insights for compound safety assessment and informed planning of subsequent studies.
Using sensitive transgenic models such as rasH2 and p53+/- mice, we evaluate tumor development within approximately six months. These accelerated studies provide reliable, mechanism-informed carcinogenicity data, allowing early-stage risk assessment with precise dosing, longitudinal monitoring, and comprehensive tumor evaluation.
We perform site-specific bioassays, including skin, inhalation, and implantation studies. This approach enables focused evaluation of local tissue responses and tumor formation, generating detailed, route-specific carcinogenicity data that complements systemic and whole-animal assessments.
We conduct bacterial reverse mutation assays using Salmonellaand E.coli strains to detect compound-induced genetic mutations. These rapid, reliable assays provide essential preliminary genotoxicity data, informing in vitro and in vivo testing strategies and supporting early-stage carcinogenicity evaluation.
We offer mammalian cell-based genotoxicity testing, including micronucleus, comet, and chromosomal aberration assays. These tests provide mechanistic insights into DNA damage, chromosomal instability, and mutation potential, forming a crucial component of comprehensive carcinogenicity assessment strategies.
We utilize rat embryonic fibroblasts and mouse skin fibroblast models to evaluate non-genotoxic carcinogenic mechanisms. These assays assess cellular transformation and tumorigenic potential in vitro, complementing genetic and in vivo data, and supporting a more complete understanding of compound carcinogenic risk.
We provide in vitro genotoxicity screening using multiple standardized assays. This early-stage testing identifies mutagenic potential, informs dose selection, guides in vivo study design, and supports mechanistic understanding of DNA damage pathways for comprehensive carcinogenicity assessment.
We employ structure-based computational models, including QSAR approaches, to predict compound carcinogenicity. This early-stage, mechanism-informed evaluation helps prioritize compounds for experimental testing, supports strategic decision-making, and complements in vitro and in vivo study data.
BOC Sciences offers a wide range of carcinogenicity testing solutions to meet your research and project timelines.
Our Carcinogenicity Testing services support a wide variety of sample types to evaluate potential cancer risk and long-term safety.
Provide your samples or product information, and our experts will deliver tailored carcinogenicity testing strategies with fast, professional guidance.
We offer an advanced technology platform and professional team to provide comprehensive carcinogenicity testing services, ensuring high-quality, efficient, and reliable data support. Examples of instruments and platforms for carcinogenicity testing at BOC Sciences:
| Platform / Category | Instruments & Systems |
| Cell Culture & Handling | High-throughput cell culture systems, automated handling platforms |
| Genotoxicity & Mutation Analysis | Micronucleus test equipment, automated Ames test systems, Comet assay imaging systems |
| Protein & Molecular Analysis | Western blot, ELISA, flow cytometer, real-time qPCR |
| High-Throughput Imaging & Analysis | Automated microscopes, high-resolution imaging analysis software |
| Animal Cells & Tissue Analysis | In vitro 3D culture systems, histological staining and image analysis equipment |
| Data Management & Analysis | Laboratory Information Management System (LIMS), statistical analysis and visualization tools |
Clients provide sample details and testing objectives. Our experts clarify goals and propose a customized carcinogenicity testing plan.
We develop a tailored study plan, defining assays, exposure conditions, and timelines to ensure efficient and accurate testing progression.
Samples undergo in vitro and in vivo testing, including genotoxicity and mutagenicity assays, with rigorous QC ensuring robust, reproducible results.
Comprehensive reports summarize results and insights, with clear documentation provided to support client review and decision-making.
We deliver customized genotoxicity and carcinogenicity testing for novel biologics and biopharmaceuticals, including in vitro and in vivo assays. Our tailored approach ensures precise detection of potential risks, supporting biotech companies in advancing R&D efficiently.
We provide comprehensive carcinogenicity testing for small molecule candidates, covering mechanistic studies and long-term bioassays. Our solution enables pharmaceutical developers to identify early safety concerns, optimize lead compounds, and streamline preclinical evaluation.
We offer flexible carcinogenicity testing solutions for niche and specialty pharmaceuticals, integrating customized study design and detailed reporting. This service helps clients understand long-term safety profiles and make informed decisions for innovative drug candidates.
We support CROs and research partners with tailored carcinogenicity testing workflows, from in vitro screens to in vivo models. Our collaborative approach enhances data reliability, accelerates project timelines, and strengthens service offerings for multiple client portfolios.
Partner with BOC Sciences to initiate your carcinogenicity testing services. Our team delivers comprehensive and reliable testing data to support your compound evaluation, enabling faster decision-making and efficient project progression.
We offer multi-tiered testing strategies that efficiently identify potential carcinogens across diverse chemical and biological samples.
Our integrated in vitro and in vivo platforms simulate realistic biological responses, ensuring predictive and reliable carcinogenicity results.
We leverage automated, high-throughput workflows to process large sample volumes while maintaining robust data quality and reproducibility.
Our reporting delivers clear, actionable insights aligned with international testing expectations, supporting informed safety and risk decisions.
Client Needs: A biopharmaceutical company developing a new kinase inhibitor sought comprehensive carcinogenicity assessment to support preclinical safety profiling and optimize candidate selection.
Challenges: The client needed to detect potential organ-specific proliferative responses and long-term tumorigenic risk, which conventional short-term tests could not reveal.
Solution: BOC Sciences designed a two-year in vivo carcinogenicity study, integrating multi-organ histopathology, tumor incidence monitoring, and targeted biomarker panels. Advanced imaging and tissue sampling strategies enabled early detection of proliferative lesions and subtle tissue changes, while robust statistical analysis ensured reproducible data.
Outcome: Delivered detailed carcinogenicity profiles highlighting tissue-specific susceptibility, allowing the client to refine molecular structure and prioritize safer candidates. This approach enhanced confidence in downstream development decisions.
Client Needs: A biotechnology company focused on immune checkpoint modulators required long-term tumor risk assessment for a promising therapeutic antibody candidate.
Challenges: The client faced difficulty capturing delayed tumorigenic events in lymphoid tissues, as conventional short-duration studies lacked sensitivity for subtle proliferative changes.
Solution: BOC Sciences implemented an integrated carcinogenicity testing program combining chronic in vivo exposure, lymphoid tissue-specific histopathology, and serum biomarker evaluation. Periodic imaging and molecular assays tracked early neoplastic changes, while longitudinal statistical modeling ensured data robustness.
Outcome: High-definition risk maps identified potential tissue-specific tumorigenesis, enabling molecular optimization and candidate ranking, equipping the client with actionable insights to advance the most promising immunomodulator safely.
Client Needs: A pharmaceutical company developing a targeted oncology therapy required a thorough carcinogenicity assessment to support preclinical optimization and compound prioritization.
Challenges: The client needed to assess off-target proliferative effects and subtle tissue changes that conventional endpoints could not reliably detect, to evaluate long-term tumor risk.
Solution: BOC Sciences applied a structured carcinogenicity testing strategy, integrating multi-dose in vivo studies, tissue-specific histopathology, and advanced molecular biomarkers. High-frequency sampling and kinetic modeling captured early neoplastic events, providing robust, reproducible longitudinal data.
Outcome: Produced precise carcinogenicity profiles, identifying dose- and tissue-specific tumor risks. Insights allowed targeted molecular refinement and confident prioritization of safer oncology candidates for further development.
A carcinogenicity test is a systematic evaluation to determine whether a chemical or new compound may cause cancer under long-term exposure. It typically combines long-term in vivo animal studies with in vitro mechanistic investigations, providing essential data for safety assessment during the research and development phase. These results help research teams understand potential risks and optimize molecular design or safety strategies. BOC Sciences has extensive experience in carcinogenicity testing, offering end-to-end support from study design to data analysis.
Carcinogenicity refers to the ability of a substance or compound to induce cancer or promote abnormal cell proliferation in biological systems. This property is often closely related to chemical structure, metabolic products, and interactions with DNA. Professional carcinogenicity evaluation helps R&D teams identify high-risk compounds early, allowing for informed decision-making and development optimization. BOC Sciences assists clients in mechanism analysis and risk stratification, providing scientific support for strategic planning.
Carcinogenicity studies are typically required when a new compound is intended for long-term use or exposure, or when there is potential for DNA damage or chronic toxicity. Drug candidates, industrial chemicals, and food additives often require such assessments to support safety optimization and molecular development. Early study design is critical to select the appropriate model and dosing regimen, and BOC Sciences can provide customized study design services to meet specific research needs.
Carcinogenicity studies are generally long-term in vivo experiments, with duration depending on the selected animal model and study design, often ranging from several months up to two years. During this period, animal health, body weight, and tumor development are continuously monitored, and data are systematically analyzed. BOC Sciences offers professional long-term animal study management and data analysis to ensure study continuity and reliable results.
Several factors can affect the results of a carcinogenicity study, including compound dose, route of administration, choice of animal model, exposure duration, and study conditions. Metabolic products and genetic background also play a role in outcomes. Precise control of experimental variables and robust data analysis are essential for reliable conclusions. BOC Sciences provides expert study design and statistical analysis services to deliver credible carcinogenicity assessment results.
BOC Sciences' carcinogenicity testing services provided highly robust and scientifically sound study designs. Their team's expertise in selecting appropriate models and endpoints ensured our data was both comprehensive and actionable. This support has greatly enhanced our internal project decision-making.
— Dr. M., Senior Research Scientist, Specialty Pharma Company
The carcinogenicity studies conducted by BOC Sciences included meticulous data collection and thorough interpretation. Their detailed analysis allowed us to confidently assess compound safety profiles and facilitated informed strategic planning within our R&D team.
— Dr. S., Head of Preclinical Research, Emerging Biotech Firm
We relied on BOC Sciences for our long-term carcinogenicity assessments and consistently received reproducible, high-quality datasets. Their attention to methodological rigor and experimental consistency has strengthened our internal compound evaluation framework.
— Dr. T., Principal Scientist, Pharmaceutical Development Group
BOC Sciences' team demonstrated exceptional technical expertise throughout our carcinogenicity testing projects. Their ability to provide clear explanations and support data interpretation allowed our research teams to make informed decisions efficiently, enhancing overall project workflow.
— Dr. A., Senior Scientist, Biopharmaceutical Company
